True North Therapeutics Inc.
Selectively inhibiting the complement system
This article was originally published in Start Up
True North Therapeutics Inc. aims to develop a monoclonal antibody that acts as a complement inhibitor to shut down a key actor of the innate immune system known as the complement system. True North believes its preclinical candidate will work early in the complement pathway and be selective to C1s, thus shutting down only the “classic” complement pathway activated by antigen-antibody (immune) complexes.